

1 **Low-MBL producing genotypes playing a role on protection to leprosy and its**  
2 **multibacillary forms in a highly endemic area for leprosy in Brazil**

3

4 **Erika M. de Salles<sup>a,b,1</sup>, Lívia M. Martins<sup>b,1</sup>, Rita de C. M. Escocard<sup>b</sup>, Bruno V. G. Forte<sup>b</sup>,**  
5 **Yonnara E. C. Maciel<sup>b</sup>, Thereza L. Kipnis<sup>b</sup>, Edilbert P. Nahn Jr.<sup>c</sup>, Wilmar D. da Silva<sup>b,d,2</sup>, Alba**  
6 **L. Peixoto-Rangel<sup>b,2\*</sup>**

7

8 <sup>a</sup>Instituto de Ciências Biomédicas, Departamento de Imunologia, Universidade de São Paulo,  
9 São Paulo, SP, Brazil

10

11 <sup>b</sup>Laboratório de Biologia do Reconhecer, Centro de Bociências e Biotecnologia, Universidade  
12 Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, Brazil

13

14 <sup>c</sup>Faculdade de Medicina de Campos, Campos dos Goytacazes, RJ, Brazil

15

16 <sup>d</sup>Laboratório de Imunoquímica, Instituto Butantan, São Paulo, SP, Brazil

17

18

19

20 **Thereza L. Kipnis<sup>2</sup>: *In memoriam*:** Her recognized visionary academic in *M. leprae* initiatives stimulated the  
21 integration of UENF and its social surroundings.

22

<sup>1</sup>These authors contributed equally to this work.

23

<sup>2</sup>These authors also contributed equally to this work.

24

25 **Running head:** MBL2 gene polymorphism and susceptibility to leprosy

26

27

28 \* Corresponding author

29 Avenida Alberto Lamego, 2000 – Parque California. Campos dos Goytacazes/RJ – Brazil.

30

E-mail: [alba@uenf.br](mailto:alba@uenf.br)

31

Telephone number: +55 (22) 2739-7255

32

33

34

35

36

37

38 **Abstract**

39

40 The high frequency of *MBL2* mutant alleles found in various human populations suggests  
41 that they provide some selective advantage. One of the hypotheses is that MBL deficiency  
42 may be protective against intracellular pathogens, including *Mycobacterium leprae*. In this  
43 study, we investigated the role of *MBL2* in the susceptibility to leprosy. Single-nucleotide  
44 variants (SNV) B (rs1800450) and C (rs1800451) in exon 1 of the *MBL2* gene and serum MBL  
45 concentrations were assessed in 53 patients with leprosy and 68 healthy controls from  
46 southeast Brazil by polymerase chain reaction followed by restriction fragment length  
47 polymorphism and commercial capture enzyme-linked immunosorbent assay, respectively.  
48 The genotyped SNVs were significantly associated with increased protection against leprosy  
49 (OR=0.3757, 95% CI=0.1615-0.8740, p=0.0273) and more severe forms, including  
50 multibacillary (OR=0.3769, 95% CI=0.1447-0.9818, p=0.0493) and lepromatous (OR=0.2423,  
51 95% CI=0.06547-0.8968, p=0.0369) leprosy. On the other hand, low-MBL producing  
52 genotypes were associated with the protection for leprosy, especially in its more severe  
53 forms. Low MBL levels and low MBL producing variants were associated with protection  
54 against leprosy and progression to more severe forms of this disease. Moreover, this study  
55 highlights MBL as a regulator of immune function in which alterations may affect normal  
56 responses to leprosy infection and inflammatory stimuli.

57 **Keywords:** Leprosy; Mannose binding lectin; Polymorphism; *Mycobacterium leprae*; SNV;  
58 Complement System

59

60

61

62

## 63 Introduction

64 Leprosy is a chronic infectious disease caused by the obligate intracellular bacillus  
65 *Mycobacterium leprae* that primarily affects the skin and peripheral nerves.<sup>1</sup> Most  
66 individuals are inherently resistant to leprosy and only a small group develops the disease  
67 after exposure to *M. leprae* for long periods. Leprosy is characterized by a wide spectrum of  
68 immunologically-defined clinical manifestations. The most severe manifestation is the  
69 lepromatous form, characterized by the absence of specific cellular immunity leading to  
70 widely disseminated disease and extended multibacillary lesions. The other end of the  
71 spectrum is represented by the tuberculoid form, which is associated with a vigorous Th1  
72 response and paucibacillary lesions.<sup>2,3</sup> Innate immunity molecules such as mannose-binding  
73 lectin (MBL) play an important role on host defense against infections due to their ability to  
74 activate the complement system and mediate the lysis and opsonization of microorganisms,  
75 and may be involved in the modulation of the immune response to infection with *M. leprae*.<sup>4</sup>  
76 The mannose-binding lectin (MBL) pathway involves a C-type lectin, which binds to  
77 mannose-containing carbohydrates in microorganisms. MBL levels are genetically  
78 determined and may be associated with increased susceptibility to infection by viruses,  
79 bacteria, fungi, and protozoa.<sup>5, 6, 7</sup> However, it has been proposed that MBL deficiency may  
80 protect the host against intracellular entry by *M. leprae* by reducing the opsonization  
81 through the deposition of multiple C3b fragments on the microbial cell surface, resulting in  
82 lower phagocytic uptake of bacilli.<sup>8, 22</sup> MBL acts as a pattern recognition molecule for a wide  
83 range of infectious agents, recognizing sugar moieties such as mannose, N-  
84 acetylglucosamine, fucose, and glucose present on the surface of several microorganisms,  
85 leading to their phagocytosis and activation of complement.<sup>9, 19</sup>

86 In humans, the gene encoding *MBL2* is located on the long arm of chromosome 10  
87 (q11.2-q21) and includes four exons. MBL serum levels are strongly affected by structural  
88 mutations in exon 1 and promoter region of the gene. A single-nucleotide variant (SNV) was  
89 found at codon 54 (allele B, Gly54Asp) in exon 1 of the *MBL2* gene,<sup>10</sup> and subsequent studies  
90 have revealed the presence of two SNVs at codons 52 (allele D, Arg52Cys) and 57 (allele C,  
91 Gly57Glu).<sup>11</sup> The alleles derived from SNVs at codons 52, 54, and 57 are termed *MBL-D*, *MBL-*  
92 *B*, and *MBL-C*, respectively, and are associated with a significant decrease in MBL levels as  
93 compared to levels in individuals carrying both copies of the normal allele, termed *MBL-A*.<sup>11</sup>  
94 <sup>12, 13</sup> In addition, three SNVs (termed “H/L”, “Y/X”, and “P/Q”) in the promoter region affect  
95 MBL serum concentration. The combination of SNVs results in three haplotypes (HYPA, LYPA,  
96 and LYQA) that are associated with normal MBL levels and four haplotypes (LXPA, LYPB,  
97 LYQC, and HYPD) associated with low or very low MBL levels.<sup>14</sup> It is possible that these  
98 variants have been maintained at high frequencies because they provide some selective  
99 advantage to the host.<sup>9, 11, 15</sup> Thus, MBL variants may be conserved mostly in heterozygous  
100 individuals. Even though some studies have shown the involvement of the complement  
101 system in leprosy, few have investigated the role of *MBL2* gene variants on infection with *M.*  
102 *leprae* and disease progression. In addition, the genetic diversity of human populations hints  
103 at the existence of yet undescribed point mutations in some polymorphic genes that warrant  
104 investigation, particularly those with a putative involvement in infectious diseases. In Brazil,  
105 infection with *M. leprae* has been reported in different geographic regions.<sup>21, 22, 24</sup> However,  
106 these findings have not been extensively validated. Here we investigated a geographically  
107 distinct population from the Southeast Brazil in order to evaluate the role of the *MBL2* gene  
108 and MBL protein in leprosy susceptibility. The present study provides novel information on

109 the association between *MBL2* gene variant and susceptibility to leprosy across the  
110 spectrum of leprosy forms.

111

## 112 **Material and Methods**

### 113 **Subjects**

114 Cases and controls were recruited in Campos dos Goytacazes, Rio de Janeiro,  
115 southeast Brazil (21° 45' 15" S and 41° 19' 28" W, 13 m asl). Fifty-three patients with leprosy  
116 were selected at the Hansen Health Program of the Campos dos Goytacazes Health  
117 Secretariat, a regional reference center for treatment of leprosy. Diagnosis was based on  
118 clinical examination and bacilloscopy of suspected tissue lesions. Bacillary lesion counts and  
119 associated typical histopathology parameters permit diagnosis and classification of leprosy  
120 forms (Table 1).<sup>16, 17</sup> Healthy controls consisted of 68 unrelated individuals recruited from  
121 the local blood bank (Table 1). Patients (L) and control subjects (HC) were from the same  
122 geographical area. Leprosy patients were grouped according to the World Health  
123 Organization (WHO) classification in multibacillary (MB) or paucibacillary (PB) leprosy and  
124 the Madrid classification in lepromatous leprosy (LL), dimorph leprosy (DL), indeterminate  
125 leprosy (IDL), and tuberculoid leprosy (TL) for the analysis (Table 1). The exclusion criteria for  
126 subjects were other infectious or inflammatory disease. Informed consent (written) was  
127 obtained from all participants and the study was approved by the local Medical Ethics  
128 Committee (n°. 1.687.476).

129

130

131

132

133 **Table 1: Clinical profile of patients with leprosy.**

	Clinical Groups (WHO)	Clinical Groups (Ridley and Joplin)	N	Age Mean $\pm$ SD (Range)	Gender Female/Male (%)
Leprosy (L)	Multibacillary (MB)	Lepromatous (LL)	23	45.78 $\pm$ 18.81 (20-91)	21.74/78.26
		Dimorph (DL)	14	49.3 $\pm$ 14.3 (30-75)	50/50
	Paucibacillary (PB)	Indeterminate (IDL)	5	30.40 $\pm$ 15.7 (10-51)	60.00/40.00
		Tuberculoid (TL)	11	40.1 $\pm$ 16.9 (9-69)	36.4/63.6
	Total		53	45.0 $\pm$ 19.2 (9-91)	35.85/64.15
	Healthy Controls (HC)		68	35.8 $\pm$ 11 (19-60)	17.6/82.4

134

135

136 **Serum MBL level measurement**

137 Serum MBL concentrations were determined using a commercial capture enzyme-  
 138 linked immunosorbent assay (MBP-oligomer ELISA, Microwell strip version; Antibody Shop,  
 139 Copenhagen, Denmark). Serum (1:100) was added to ELISA microplates coated with  
 140 monoclonal antibody against the oligomeric MBL carbohydrate-binding domain. The bound  
 141 MBL was detected by a second biotin-labeled antibody and streptavidin peroxidase,  
 142 followed by the addition of tetramethylbenzidine (TMB). Color intensity was read in an ELISA  
 143 reader at 450 nm (Multiskan EX Primary EIA, Thermo Fisher, Waltham, MA, USA). The serum  
 144 standard results were used to build a calibration curve. MBL concentrations are defined as

145 low (< 100 ng/ml), intermediate (100–1000 ng/ml), and high (< 1000 ng/ml) according to the  
146 kit manufacturer's instructions.

147

#### 148 ***MBL2* genotyping**

149 The exon 1 region of *MBL2* (codons 54 and 57 for alleles B and C, respectively) was  
150 genotyped by allele-specific polymerase chain reaction followed by restriction fragment  
151 length polymorphism (PCR-RFLP). The forward and reverse primers used were 5'–  
152 AGTCGACCCAGATTGTAGGACAGAG–3' and R: 5'–AGGATCCAGGCAGTTTCCTCTGGAA GG–3',  
153 respectively, as described elsewhere.<sup>18</sup> The PCR was performed in 25- $\mu$ l volumes containing  
154 100–500 ng (2  $\mu$ l) of genomic DNA, 0.5  $\mu$ l of specific primers (12.5 pmol/ml; Fermentas,  
155 Waltham, MA, USA), 10 mM deoxynucleotide triphosphates (Fermentas, USA), 1.25  $\mu$ l MgCl<sub>2</sub>  
156 (50 mM; Invitrogen, Carlsbad, CA, USA), 2.5  $\mu$ l 10 $\times$  PCR buffer (without magnesium), and 1 U  
157 of *taq* platinum polymerase (Invitrogen, USA). The following reaction conditions were used:  
158 94 °C for 2 min, 35 cycles at 94 °C for 30 s, followed by annealing at 60 °C for 30 s and 72 °C  
159 for 2 min, and a final extension step of 5 min at 72 °C. The PCR products were identified by  
160 electrophoresis in 2% (w/v) agarose gel stained with ethidium bromide. The fragment  
161 amplified by PCR (349 bp) was digested using *Ban*I and *Mbo*II restriction enzymes to detect B  
162 and C alleles. The *Ban*I restriction enzyme cleaved the MBL\*A allele into two fragments (260  
163 and 89 bp) and the MBL\*B allele was not cleaved; *Mbo*II cleaved the MBL\*C allele into two  
164 fragments (279 and 70 bp). Fragments were visualized by electrophoresis in 8%  
165 polyacrylamide gel stained with ethidium bromide.

166

167

168

## 169 **Statistical analysis**

170 MBL levels were compared between leprosy patients and healthy controls using the  
171 Kruskal-Wallis test followed by Dunn's or Mann-Whitney tests. The allelic and genotypic  
172 frequencies were compared using Fisher's exact test. The associations were represented by  
173 odds ratios (ORs) with 95% confidence intervals (CIs). Differences were considered  
174 significant at  $p < 0.05$ . The analyses were performed using GraphPad Prism™ 5.0 (GraphPad  
175 Software, San Diego, CA, USA). Hardy-Weinberg equilibrium (HWE) was calculated for each  
176 SNV in a set of unrelated controls with a customized spreadsheet in Microsoft Excel.

177

## 178 **Results**

### 179 **Serum MBL levels in patients and healthy controls**

180 MBL serum levels ranged from 0.0 to 3903.0 ng/ml (median = 1983.0 ng/ml) in HC and  
181 0.1 to 3024.8 ng/ml (median = 560.0 ng/ml) in L patients. There were no significant  
182 differences between L and HC groups ( $p = 0.2042$ ) and in the comparison among patients  
183 with severe forms of the disease (MB and LL) and patients with less severe forms ( $p = 0.3588$   
184 and  $0.5678$ , respectively) (Fig. 1). Leprosy patients were also assessed according to MBL  
185 production levels. The frequency of low- ( $< 100$  ng/ml), intermediate- ( $100\text{--}1000$  ng/ml), and  
186 high- ( $> 1000$  ng/ml) MBL producers was similar between groups with different degrees of  
187 disease severity (Fig. 1).

188

189 **Figure 1:** Serum MBL levels (dot plot graphs), and frequencies (parts of whole graphs) were measured by  
190 ELISA and plotted according to the presence or absence of leprosy (**A**); or according to WHO classification (**B**)  
191 or Madri classification (**C**). Individuals were considered low producers with up to 100 ng/ml, medium with 100  
192 to 1000 ng/ml and high producers above 1000 ng/ml of MBL in sera.

193



194 **Allelic and genotypic distribution of SNV B (rs1800450) and C (rs1800451)**

195           Only three individuals in the studied population had the C (rs1800451) allele: one  
196 individual with the DL form and two HCs, corresponding to a frequency of 0.025. The B allele  
197 (rs1800450) had a frequency of 0.2 in the population. When grouped according to presence  
198 or absence of leprosy, the frequencies of alleles B and C in the L and HC groups were 0.08  
199 and 0.17, respectively. The presence of allele B was protective for the development of  
200 leprosy (OR = 0.375, 95% CI = 0.1567-0.8977, p = 0.0387) and the progression to  
201 multibacillary forms of the disease (OR = 0.348, 95% CI = 0.1298-0.9704, p = 0.0441) (**Table**  
202 **2**).

203

204

205 **Table 2: Allele and genotype distribution in subjects with leprosy and healthy controls relative to the single nucleotide variants B.**  
206

Clinical form	Genotype AA (frequency)	Genotype AB (frequency)	<i>p</i>	OR (95% CI)	Allele A (frequency)	Allele B (frequency)	<i>p</i>	OR (95% CI)
<b>Lepromatous</b>	20 (0.87)	3 (0.13)	0.0633	0.275 (0.07407 - 1.021)	43 (0.935)	3 (0.065)	0.0915	0.3256 (0.09319 – 1.138)
<b>Borderline</b>	11 (0.786)	3 (0.214)	0.3691	0.5500 (0.1379 – 2.193)	25 (0.893)	3 (0.107)	0.5755	0.5600 (0.1563 – 2.007)
<b>Indeterminate</b>	5 (1)	0 (0)	0.1644	0.1651 (0.008751 – 3.116)	10 (1)	0 (0)	0.3689	0.2187 (0.1238 – 3.861)
<b>Tuberculoid</b>	8 (0.727)	3 (0.273)	0.7402	0.6875 (0.1666 – 2.837)	19 (0.864)	3 (0.136)	0.7690	0.7368 (0.2018 – 2.691)
<b>Paucibacilar</b>	13 (0.813)	3 (0.227)	0.2472	0.4231 (0.1096 – 1.163)	29 (0.906)	3 (0.094)	0.2989	0.4828 (0.1358 – 1.716)
<b>Multibacilar</b>	31 (0.838)	6 (0.162)	<b>0.0441</b>	<b>0.3548</b> <b>(0.1298 – 0.9704)</b>	68 (0.919)	6 (0.081)	0.0654	0.4118 (0.1602 – 1.059)
<b>Leprosy</b>	44 (0.83)	9 (0.17)	<b>0.0387</b>	<b>0.3750</b> <b>(0.1567-0.8977)</b>	97 (0.915)	9 (0.085)	0.0578	<b>0.4330</b> <b>(0.1920 - 0.9763)</b>
<b>Control</b>	44 (0.647)	24 (0.353)	-	-	112 (0.824)	24 (0.176)	-	-

208           To evaluate the protective role of variants in the *MBL* gene in the development  
209   and severity of leprosy, the frequency of alleles B and C was combined in a group  
210   named A0. Overall, *MBL* variants were associated with increased protection against  
211   leprosy (OR = 0.3757, 95% CI = 0.1615–0.8740,  $p = 0.0273$ ), and their most severe  
212   forms according to WHO (MB: OR = 0.3769, 95% CI = 0.1447–0.9818,  $p = 0.0493$ ) and  
213   Madrid classifications (LL: OR = 0.2423, 95% CI = 0.06547–0.8968,  $p = 0.0369$ ) (**Table**  
214   **3**). These results show that variants B and C are protective against the development of  
215   leprosy, especially in its more severe forms.

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231 **Table 3: Allele and genotype distribution in subjects with leprosy and healthy controls relative to the single nucleotide variants B and C**  
 232 **combined.**  
 233

234

235

236

237

238

239

240

241

Clinical form	Genotype AA (frequency)	Genotype AO (frequency)	<i>p</i>	OR (95% CI)	Allele A (frequency)	Allele O (frequency)	<i>p</i>	OR (95% CI)
<b>Lepromatous</b>	20 (0.87)	3 (0.13)	<b>0.0369</b>	<b>0.2423</b> <b>(0.06547 – 0.8968)</b>	43 (0.935)	3 (0.065)	0.0603	0.2952 (0.08488 – 1.026)
<b>Borderline</b>	10 (0.714)	4 (0.286)	0.5583	0.6462 (0.1834 - 2.275)	24 (0.857)	4 (0.143)	0.7885	0.7051 (0.2251 – 2.209)
<b>Indeterminate</b>	5 (1)	0 (0)	0.1533	0.1458 (0.007737 – 2.747)	10 (1)	0 (0)	0.2094	0.1986 (0.1127 – 3.499)
<b>Tuberculoid</b>	8 (0.727)	3 (0.273)	0.7375	0.6058 (0.1472 – 2.492)	19 (0.864)	3 (0.136)	0.7677	0.6680 (0.1837 - 2.429)
<b>Paucibacilar</b>	13 (0.812)	3 (0.188)	0.2415	0.3728 (0.09687 – 1.435)	29 (0.906)	3 (0.094)	0.2972	0.4377 (0.1237 - 1.548)
<b>Multibacilar</b>	30 (0.811)	7 (0.189)	<b>0.0493</b>	<b>0.3769</b> <b>(0.1447 - 0.9818)</b>	67 (0.905)	7 (0.095)	0.0757	0.4420 (0.1818 – 1.075)
<b>Leprosy</b>	43 (0.811)	10 (0.189)	<b>0.0273</b>	<b>0.3757</b> <b>(0.1615 – 0.8740)</b>	96 (0.906)	10 (0.094)	<b>0.0448</b>	<b>0.4407</b> <b>(0.2022 - 0.9606)</b>
<b>Control</b>	42 (0.727)	26 (0.273)	-	-	110 (0.809)	26 (0.191)	-	-

## 242 **MBL serum levels and their association with MBL genetic variants**

243 MBL serum levels were significantly lower in genotype A0 individuals than in AA  
244 individuals ( $p = 0.0025$ ). When comparing A0 and AA genotypes in L and HC subjects, L  
245 individuals with A0 genotype had significantly lower MBL serum levels than those with  
246 AA genotype ( $p=0,0021$ ). Thus, the results indicate that carrying the ancestral  
247 genotype (AA) is related to the highest levels of MBL, while to have the polymorphic  
248 variant (A0) can be associated to lower MBL production.

249

250 **Figure 2:** MBL production associated with *MBL2* genotypes (A) in all subjects and (B) in leprosy  
251 patients and healthy control. The levels of MBL were compared with Mann-Whitney test. Significance  
252 was considered at  $p < 0.05$ ,  $p < 0.01$  or  $p < 0.001$  as represented by \*, \*\* and \*\*\*, respectively.

253

## 254 **Discussion**

255

256

257 In this study, we investigated a geographically distinct population from the  
258 Southeast Brazil in order to evaluate the role of *MBL2* gene and MBL protein in the  
259 leprosy susceptibility. We found no significant association between MBL levels and  
260 leprosy when the analysis did not separate individuals by their genotypes, i.e.,  
261 considering only the levels of MBL in the patients and controls sera (Fig.1). The normal  
262 levels of MBL in serum are very stable,<sup>25</sup> but may range from 3 to 50 ng/ml in different  
263 individuals. Due to this wide variation in MBL levels and since sample size was very  
264 small, this dosage shall be further tested in larger samples.

265 The variation in MBL levels can be explained by the occurrence of four allotypes  
266 due to mutations in exon 1 of the gene encoding the MBL polypeptide as well as  
267 several variants in the promoter region. In our study, we evaluated the genetic variants

268 in exon 1 of *MBL2* gene (B and C alleles) and found that B variant (rs1800450) was  
269 associated with increased protection against leprosy (OR = 0.375, 95% CI =  
270 0.1567–0.8977,  $p = 0.0387$ ) and multibacillary forms of this disease (OR = 0.348, 95% CI  
271 = 0.1298–0.9704,  $p = 0.0441$ ), and this effect remained significant even after alleles B  
272 and C were combined in a group called A0 (leprosy: OR = 0.3757,  $p = 0.0273$ ;  
273 multibacillary form, MB: OR = 0.3769,  $p = 0.0493$ ; and lepromatous leprosy, LL: OR =  
274 0.2423,  $p = 0.0369$ ). Our findings are partially similar to those of Sapkota et al.,<sup>22</sup> who  
275 suggested a protective role for MBL deficiency against the development of the more  
276 severe multibacillary form of leprosy, but not for leprosy. However, their findings were  
277 based on protein levels only, unlike the our study that combined data on MBL levels  
278 and *MBL2* variant to define MBL deficiency. Another interesting finding of the current  
279 study is the distribution of *MBL2* genotypes (AA and A0): the frequencies of genotypes  
280 associated with low and intermediate MBL levels were significantly higher in leprosy  
281 (L) patients with A0 genotype than with AA genotype ( $p = 0.0021$ ). This result indicates  
282 that genotype A0 was associated with significantly decreased risk of leprosy and  
283 manifestation of more severe forms of the disease, lending further support to the idea  
284 that MBL deficiency is associated with protection against leprosy and the development  
285 of multibacillary disease. Pathogen or damage-associated molecular sugar patterns  
286 (PAMPs/DAMPs) on *M. leprae* are recognized by mannose-binding lectin (MBL) and  
287 activate the lectin pathway of complement. Autoactivation of the serine protease  
288 MASP-1 is followed by transactivation of MASP-2, cleavage of C2 and C4 and formation  
289 of the C3 convertase C2Ac4B. C3 convertase ultimately leads to the insertion of C3b  
290 opsonins on the surface of the pathogen (20). Also, increased MBL protein in serum is  
291 expected to enhance the uptake of C3b/C4b/ficolin/MBL-opsonized *M. leprae*. Thus,

292 MBL genetic variants *rs1800450* and *rs1800451* herein associated to low MBL levels,  
293 may be contributing to reduce complement activation of the lectin pathway and  
294 phagocytosis, which could be highly beneficial, protecting against leprosy disease.  
295 However, functional investigations on phagocytic efficiency of the associated genetic  
296 variants *rs1800450* and *rs1800451* would help to clarify the role of this protein in the  
297 disease. Later, yet unidentified intrinsic pathways protect *M. leprae* bacilli from  
298 macrophage defenses by inhibiting the C5b-C9 membrane lytic complex.<sup>20</sup>  
299 Nevertheless, the molecular mechanisms of immune evasion by *M. leprae* bacilli must  
300 be better understood.

301       Messias-Reason et al.<sup>20</sup> showed for the first time an association between low-  
302 MBL producing haplotypes/compound genotypes and protection against development  
303 of lepromatous and borderline leprosy. However, they also found a significant  
304 association between the high-MBL producer haplotype LYPA and both leprosy per se  
305 and its lepromatous and borderline forms, a finding similar to those described in our  
306 study.

307

## 308 **Conclusions**

309       In conclusion, this study supports a pivotal role for the MBL pathway in the  
310 susceptibility to leprosy. We showed that MBL genetic variants modulate the immune  
311 response in *M. leprae*-affected populations and are probably maintained by balancing  
312 selection, supporting previous studies of MBL and leprosy.<sup>21</sup> MBL seems to play an  
313 important role on the immune response to infection with *M. leprae*: low MBL levels

314 and low MBL producing variants were associated with protection against leprosy and  
315 progression to more severe forms of this disease.

316         Considering the high efficiency of the molecular procedure used to identify MBL  
317 haplotypes, further studies are needed to clarify the role of MBL in the fate of infected  
318 cells. Investigation involving the role of pattern recognition receptors in recognizing  
319 pathogen-associated molecular patterns, certainly will contribute for new insights into  
320 the innate immune response in leprosy immunoregulation and may indicate potential  
321 new targets for therapeutic intervention.

322

### 323 **Abbreviations**

324 MBL: mannose binding-lectin; SNV: single nucleotide variant; PCR-RFLP: polymerase  
325 chain reaction- restriction fragment length polymorphism; MBP-oligomer: oligomeric  
326 MBL carbohydrate-binding domain; ELISA: enzyme linked immunosorbent assay; OR:  
327 odd ratio; CI: confidence interval; *M. leprae*: *Mycobacterium leprae*; WHO: world  
328 health organization; L: leprosy patients; HC: healthy controls; MB: multibacillary  
329 patients; PB: paucibacillary patients; LL: lepromatous leprosy; DL: dimorph leprosy;  
330 IDL: indeterminate leprosy; TL: tuberculoid leprosy; TMB: tetramethylbenzidine; DNA:  
331 deoxyribonucleic acid.

332

### 333 **Ethics approval and consent to participate**

334 The study protocol was approved by The Local Ethic Medical Committee (CAEE nº.  
335 19679119.8.0000.5244). Written informed consents were obtained from the  
336 participants and/or yours parents/guardians of the participating children.

337



338 **Consent for publication**

339 Not applicable.

340

341 **Availability of data and materials**

342 The dataset supporting the findings of this article is available from the corresponding  
343 author upon request.

344

345 **Competing interests**

346 The authors declare that they have no competing interests.

347

348 **Funding**

349 This project has been supported by Foundation Carlos Chagas Filho Research Support  
350 of the State of Rio de Janeiro (FAPERJ) - APQ-1 E-26/111.196/2014. The funders had no  
351 role in study design, data collection and analysis, decision to publish, or preparation of  
352 the manuscript.

353

354 **Authors' contributions**

355 EMS, acquisition of data and drafting of manuscript; LMM, analysis and interpretation  
356 of data; RCME, acquisition of data; BVGF, acquisition of data; YECM, acquisition of  
357 data; TLK, In memoriam; EPNJr, clinical examination of patients; WDS, analysis of  
358 data; ALPR, study conception and design, interpretation of data, and drafting of  
359 manuscript.

360

361 **Acknowledgements**

362 We thank Hansen Health Program of the Campos dos Goytacazes Health Secretariat  
363 and the dermatologist Edilbert P. Nahn Jr. for their hard work and technical expertise  
364 in selecting patients and collecting biological material. We also thank the local Blood  
365 Bank from Ferreira Machado Hospital, Campos dos Goytacazes medical staff, in  
366 selecting healthy controls and collecting biological material.




367

## 368 **References**

- 369 1. Ridley DS, Jopling WH, 1966. Classification of leprosy according to immunity. A five-  
370 group system. *Int J Lepr Other Mycobact Dis* 34: 255-273.  
371
- 372 2. Abulafia J, Vignale RA, 1999. Leprosy: pathogenesis updated. *Int J Dermatol* 38: 321-  
373 334.  
374
- 375 3. Goulart IM, Penna GO, Cunha G, 2002. Immunopathology of leprosy: the complexity of  
376 the mechanisms of host immune response to Mycobacterium leprae. *Rev Soc Bras*  
377 *Med Trop* 35: 365-375.  
378
- 379 4. Prodinger WM, 1999. Complement receptor type two (CR2,CR21): a target for  
380 influencing the humoral immune response and antigen-trapping. *Immunol Res* 20: 187-  
381 194.  
382
- 383 5. Das BK, Panda AK, 2015. MBL-2 polymorphisms (codon 54 and Y-221X) and low MBL  
384 levels are associated with susceptibility to multi organ dysfunction in P. falciparum  
385 malaria in Odisha, India. *Front Microbiol* 6: 778.  
386
- 387 6. Yanagisawa K, Ogawa Y, Uchiumi H, Gohda F, Mawatari M, Ishizaki T, Mitsui T,  
388 Yokohama A, Handa H, Tsukamoto N, et al., 2015. Gene polymorphisms of mannose-  
389 binding lectin confer susceptibility to Pneumocystis pneumonia in HIV-infected  
390 patients. *J Infect Chemother* 21: 769-775.  
391
- 392 7. Liu L, Ning B, 2015. The role of MBL2 gene polymorphism in sepsis incidence. *Int J Clin*  
393 *Exp Pathol* 8: 15123-15127.  
394
- 395 8. Turner MW, 2003. The role of mannose-binding lectin in health and disease. *Mol*  
396 *Immunol* 40: 423-429.  
397
- 398 9. Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A, 1994. Dual role of mannan-  
399 binding protein in infections: another case of heterosis? *Eur J Immunogenet* 21: 125-  
400 131.  
401
- 402 10. Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, Summerfield JA, 1991.  
403 Molecular basis of opsonic defect in immunodeficient children. *Lancet* 337: 1569-1570.  
404

- 405 11. Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, Summerfield JA, Turner MW,  
406 1992. High frequencies in African and non-African populations of independent  
407 mutations in the mannose binding protein gene. *Hum Mol Genet* 1: 709-715.  
408
- 409 12. Lipscombe RJ, Sumiya M, Summerfield JA, Turner MW, 1995. Distinct physicochemical  
410 characteristics of human mannose binding protein expressed by individuals of differing  
411 genotype. *Immunology* 85: 660-667.  
412
- 413 13. Walport MJ, 2001. Complement. First of two parts. *N Engl J Med* 344: 1058-1066.  
414
- 415 14. Garred P, Thiel S, Madsen HO, Ryder LP, Jensenius JC, Svejgaard A, 1992. Gene  
416 frequency and partial protein characterization of an allelic variant of mannan binding  
417 protein associated with low serum concentrations. *Clin Exp Immunol* 90: 517-521.  
418
- 419 15. Davison AR, Kooij R, Wainwright J, 1960. Classification of leprosy. 1. Application of the  
420 Madrid classification of various forms of leprosy. *Int J Lepr* 28: 113-125.  
421
- 422 16. World Health Organization, 1998. Model Prescribing Information: Drugs Used in  
423 Leprosy. Available at: <http://apps.who.int/medicinedocs/pdf/h2988e/h2988e.pdf>.  
424 Accessed May 23, 2018.  
425
- 426 17. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A, 1995.  
427 Interplay between promoter and structural gene variants control basal serum level of  
428 mannan-binding protein. *J Immunol* 155: 3013-3020.  
429
- 430 18. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC,  
431 Eggleton P, Hansen S, Holmskov U, et al., 1997. A second serine protease associated  
432 with mannan-binding lectin that activates complement. *Nature* 386: 506-510.  
433
- 434 19. Bonar A, Chmiela M, Rudnicka W, Rozalska B, 2005. Mannose-binding lectin enhances  
435 the attachment and phagocytosis of mycobacteria in vitro. *Arch Immunol Ther Exp*  
436 (*Warsz*) 53: 437-441.  
437
- 438 20. de Messias-Reason IJ, Boldt AB, Moraes Braga AC, Von Rosen Seeling Stahlke E,  
439 Dornelles L, Pereira-Ferrari L, Kremsner PG, Kun JF, 2007. The association between  
440 mannan-binding lectin gene polymorphism and clinical leprosy: new insight into an old  
441 paradigm. *J Infect Dis* 196: 1379-1385.  
442
- 443 21. Dornelles LN, Pereira-Ferrari L, Messias-Reason I, 2006. Mannan-binding lectin plasma  
444 levels in leprosy: deficiency confers protection against the lepromatous but not the  
445 tuberculoid forms. *Clin Exp Immunol* 145: 463-468.  
446
- 447 22. Sapkota BR, Macdonald M, Berrington WR, Misch EA, Ranjit C, Siddiqui MR, Kaplan G,  
448 Hawn TR, 2010. Association of TNF, MBL, and VDR polymorphisms with leprosy  
449 phenotypes. *Hum Immunol* 71: 992-998.  
450
- 451 23. Vasconcelos LR, Fonseca JP, do Carmo RF, de Mendonca TF, Pereira VR, Lucena-Silva N,  
452 Pereira LM, Moura P, Cavalcanti Mdo S, 2011. Mannose-binding lectin serum levels in  
453 patients with leprosy are influenced by age and MBL2 genotypes. *Int J Infect Dis* 15:  
454 e551-557.  
455

- 456 24. Nielsen SL, Andersen PL, Koch C, Jensenius JC, Thiel S, 1995. The level of the serum  
457 opsonin, mannan-binding protein in HIV-1 antibody-positive patients. *Clin Exp*  
458 *Immunol* 100: 219-222.  
459
- 460 25. Modlin RL, 2010. The innate immune response in leprosy. *Curr Opin Immunol* 22: 48-  
461 54.

**A****B**